1. Arnett CD, Wolf AP, Shiue CY, Fowler JS, MacGregor RR, Christman DR,Smith MR. Improve delineation of human dopamine receptors using(18F)-N-methylspiroperidol and PET. J Nucl Med 1986;27:1878–1882.
2. Delforge J, Loc’h C, Hantraye P, Stulzaft O, Khalili-Varasteh M, Mazière M, Syrota A, Mazière B. Kinetic analysis of central [76Br]bromolisuridebinding to dopamine D2 receptors studied by PET. J Cereb Blood Flow Metab 1991;11:914–925.
3. Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedstrom CG, Litton JE, Sedvall G. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA 1985;82:3863–3867.
4. Farde L, Wiesel FA, Stone-Elander S. Halldin C, Nordström A-L, Hall H. Sedvall G. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990;47:213–219.
5. Farde L, Nordström A-L, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of Central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine.relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538–544.